Frederik T. Hansen is a molecular biologist with 15 years of experience in protein science and medically-relevant natural compounds, serving as CTO and Co-Founder of Idun Biologics.  With a strong foundation in molecular and structural biology, Frederik brings deep expertise in protein engineering, cell-based assay development, and biotechnology innovation. He has held research positions at leading institutions including Aalborg University, Aarhus University, the University of Auckland, and McGill University, where he honed his skills in therapeutic protein design and functional validation. At Idun, Frederik leads the development and optimization of our technology, driving our innovation pipeline forward. His sharp scientific intuition, hands-on approach, and collaborative mindset make him an essential leader in shaping our R&D strategy and delivering breakthrough solutions in metabolic disease.

Clarisse Chiche-Lapierre is a biochemist, structural biologist, and protein engineer with a Master's degree from McGill University. As the CEO and Co-Founder of Idun Biologics, Clarisse combines her deep expertise in molecular biology with a strong engineering background to drive the development of the company's innovative platform. She leads the company's strategic vision, focusing on scientific and technical excellence potentiating our team's effort to address the consequences of metabolic disease through innovative approaches. Her commitment to scientific progress and social responsibility is at the heart of Idun Biologics' mission to make a lasting and positive impact on global health.

Aske Bedrow Bojesen holds a Master’s degree in Biotechnology from Aalborg University and brings a rigorous, hands-on approach to experimental design, analytical method development, and protein engineering. As the architect behind our validated analytical workflows, Aske has been instrumental in scaling up our protein production and ensuring the highest standards of quality and reproducibility across our operations. His deep understanding of process optimization and commitment to scientific excellence make him a driving force behind the precision and reliability of our R&D efforts.

Morten Brøndum Sørensen leads our biological research strategy with a deep commitment to scientific rigor and coordination of team efforts. He holds a Master’s degree in Biomedicine from Aalborg University, complemented by a Bachelor’s in Medicine with Industrial Specialisation. With strong expertise in cell biology, fluorescence microscopy, flow cytometry, and adipose-derived stem cells, Morten plays a key role in developing and validating both in vitro and in vivo models to evaluate the efficacy, mechanism of action, and safety of our drug candidates. He oversees assay development, ensuring that our research is both innovative and aligned with therapeutic milestones. Valued for his structured approach and natural leadership, Morten fosters collaboration and efficiency across the team, making him a vital force in driving our R&D forward. 

John D. Nieland is an entrepreneur and biotech company founder, professor of medicine and health technologies, head of Molecular Pharmacology at Aalborg University, and research with many years of experience in identifying new leads for treating complex diseases. As co-founder of 2A Pharma and 2N Pharma, and CSO of 2N Pharma, John has valuable experience in the biotech start-up world with successful track record for commercialising pharmaceutical product and managing drug development companies. Educated at the University of Amsterdam, he later established himself as a piliard of Aalborg University in Denmark, with his work providing novel therapeutic outlooks for people suffering from Multiple Sclerosis, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Huntington's disease and others.

"Give patients an opportunity to treat themselves in different ways and develop new classes of drugs. We have come a long way, but there is still a  way to go."

Torben Moos is medical doctor, university professor, textbook author and research expert in drug delivery with a focus on nervous systems and the blood/brain barrier. Torben is not only a high-profile researcher with 40 years of experience in the top-tier laboratories of Copenhagen University's Panum Institute and Lundbeck A/S among others, he is now a leader of the pioneering Medicine program with Industrial Specialisation (MEDIS) at Aalborg University. His cutting-edge research on liposomes and lipid nanoparticle set new standards for the delivery of biological particle to target cell as a therapeutic avenue.

Most likely to bring cake to a meeting and author of The Great Hangover Guide: How to Survive January 1st.

Preben Bruun-Nyzell is the CEO and co-founder of 2N Pharma who brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman of Apoglyx, a Swedish biotech focused on aquaporins. Earlier in his career, he worked for Roche in Basel and PwC in London. Previously, Preben was CFO of a company in the Middle East with 1,200 employees and sales of $1bn.

Dan Chiche has over 35 years of experience in the pharmaceutical and biotechnology industries. As our Medical Affairs advisor, he brings deep expertise in clinical development and medical strategy. Throughout his career, Dan Chiche has been involved in the clinical development of compounds across various therapeutic areas, including infectious diseases, HIV, hepatitis, influenza, oncology, rheumatoid arthritis, hypertension, diabetes, COPD, asthma, pain, fibrosis, and oncology. He has held senior leadership roles at top-tier companies including Glaxo and Bristol Myers Squibb. He served as Chief Medical Officer at several innovative biotech firms and at the NEOMED Institute in Montreal, where he focused on translating early-stage science into clinical applications. His clinical background in emergency and intensive care medicine, combined with his strategic leadership in both large pharma and start-up biotech environments, makes him an exceptional addition to our team as we advance our pipeline.